Cv Therapeutics, Inc.

Gilead Sciences, Inc.

Gilead Palo Alto, Inc.

Teon Therapeutics, Inc.

The Endowment for Research in Human Biology, Inc.

Elfatih O Elzein

Jeff A Zablocki

Venkata Poornapragnacharyulu Palle

Xiaofen Li

Rao V Kalla

Thao Perry

Prabha N Ibrahim

Dmitry Koltun

Robert H Jiang

Britton Kenneth Corkey

Eric Q Parkhill

Vaibhav Varkhedkar

Chandrasekar Venkataramani

Michael Graupe

Juan A Guerrero

Dengming Xiao

Ruben Martinez

Tetsuya Kobayashi

Tim Marquart

Luiz Belardinelli

Kevin D Shenk

Kenneth S Rehder

Brent K Blackburn

Gregory Notte

Jiwen Liu

Mark J Bartlett

Robert Seemayer

Jennifer Leigh Cosman

Travis Lemons

Grigory Nudelman

Matthew Abelman

Christopher F Morrison

Kristyna M Elbel

Michael Organ

Arvinder Dhalla

Venkata P Palle

Yaroslav Bilokin

Scott Carson Miller

Scott Preston Simonovich

Christopher Allen Ziebenhaus

Stanislas Mayer

Wing Ming Keung

Guoxin Tao

Ivan Diamond

Lina Yao

Peidong Fan

Maria Pia Arolfo

Zhan Jiang

Anthony Disanti

Peter Kernast

Jeffrey Zablocki

Venkata D-011 Oakwood Estates Palle

Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of Cannabinoid receptor 2 (CB2) or that we benefit from modulating the Cannabinoid receptor 2 (CB2).

Cannabinoid receptor type 2 (CB2) modulators and uses thereof

Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed: 

Therapeutic heterocyclic compounds

Disclosed herein are compounds of Formula (III), compositions and formulations thereof,  and methods for modulating the A2adenosine receptor for treatment of Aadenosine receptor mediated diseases or conditions.

Adenosine receptor antagonists and uses thereof

Compounds having the following Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use and preparation are disclosed: 

N-pyrazole substituted 2-adenosine compounds and methods for using the compounds as AA-adenosine receptor agonists useful to stimulate mammalian coronary vasodilation for therapeutic purposes and as adjuncts in cardiological imaging.

2-(N-pyrazolo)adenosines with application as adenosine Areceptor agonists

Disclosed is a synthesis suitable for large scale manufacture of an A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.

Process for preparing an A2A-adenosine receptor agonist and its polymorphs

The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R, R, R, R, R, R, Rand Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Fused heterocyclic compounds as CaM kinase inhibitors

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Y, Z, n, Rand Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Fused heterocyclic compounds as ion channel modulators

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R, X, X, Y and Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Z, Z, Z, Z, X, Y, R, Rand Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W, W, W, R, Q, X, Xand Xare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Growing community of inventors

Fremont, CA, United States of America

Elfatih O Elzein